Magnitude and duration of elevated gastric pH in patients infected with human immunodeficiency virus after administration of chewable, dispersible, buffered didanosine tablets.
OBJECTIVE
To test the hypothesis that gastric pH would be elevated above pH 3.0 for at least 2 hours after administration of chewable, dispersible, buffered didanosine tablets. Doses tested were 200 mg (two 100-mg tablets) and 400 mg (two 200-mg tablets). We also sought to compare these doses with regard to maximum gastric pH (pHmax), time to pHmax (TpH-max), time that gastric pH exceeds 3.0 (TpH>3), and area under the gastric pH versus time curve for pH greater than 3.0 (AUCT>pH 3).


METHODS
Prospective, parallel-group, dose-comparison, gastric pH study.


METHODS
General Clinical Research Center, University of Michigan Hospitals, Ann Arbor, Michigan.


METHODS
Nineteen patients infected with human immunodeficiency virus, aged 30-62 years, and receiving long-term didanosine therapy.


METHODS
Patients underwent continuous gastric pH monitoring, using the Heidelberg capsule radiotelemetric pH monitoring device. After documentation of a fasting baseline gastric pH below 3.0, patients were given 180 ml of water (control phase), and gastric pH was allowed to return to baseline. After administration of a single, oral dose of didanosine 200 mg or 400 mg with 180 ml of water, gastric pH was recorded until pH remained below 3.0 for 10 minutes.


RESULTS
A mean pHmax of 8.6 (range 6.3-9.5) was achieved with a TpH-max of 4.1 minutes (range 1-12.0 min). Mean TpH>3 was 24.9 minutes (range 15-55 min), with an AUCT>pH 3 of 2.6 pH x min(-1) (range 1.2-6.9 pH x min(-1)). The two doses of didanosine tested did not differ significantly in mean gastric pH parameters.


CONCLUSIONS
After administration of chewable, dispersible, buffered didanosine tablets, 200 or 400 mg, the mean duration of elevated gastric pH (TpH>3) was less than 30 minutes, with a range of 15-55 minutes. Characterization of the magnitude and duration of elevated gastric pH may allow for earlier administration of other pH-sensitive drugs. The short duration of elevated gastric pH may help explain the wide variability in didanosine bioavailability observed clinically.
DePestel
Daryl D
DD
Department of Clinical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA. daryldd@umich.edu
Kazanjian
Powel H
PH
Cinti
Sandro K
SK
Kauffman
Carol A
CA
Carver
Peggy L
PL
D000284:Administration, Oral; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D019540:Area Under Curve; D002021:Buffers; D016049:Didanosine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005753:Gastric Mucosa / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008409:Mastication; D008875:Middle Aged; D011446:Prospective Studies; D013607:Tablets; D013997:Time Factors
D019380:Anti-HIV Agents; D002021:Buffers; D013607:Tablets; D016049:Didanosine